NCT01799356

Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,303 (actual)
• Sponsor: Istanbul Bakirkoy Maternity and Children Diseases Hospital · Other Government
• Sex: Female
• Age: 14 Years – 45 Years
• Healthy volunteers: Accepted

Summary

We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days

Conditions

• Pelvic Inflammatory Disease

Interventions

Type	Name	Description
DRUG	Moxifloxacin	daily 400 mg moksifloksasin
DRUG	Ofloxacin	daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
DRUG	Metronidazole	daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID

Timeline

• Start date: 2010-06-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2013-02-26
• Last updated: 2013-08-28

Locations

4 sites across 1 country: Turkey (Türkiye)